BiotechTube
HDL Therapeutics

HDL Therapeutics

Houston, United States· Est.
hdltherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

HDL Therapeutics, founded in 2015 and based in Houston, Texas, is a private biotech company targeting cardiovascular and metabolic diseases. The company's core asset is the PDS-2™ System, which is described as the only FDA-approved therapy designed to regress coronary plaques in patients with Homozygous Familial Hypercholesterolemia (HoFH) by leveraging HDL. This positions the company with a commercial-stage product for a severe, rare disease while potentially pursuing broader atherosclerosis applications. The leadership team brings decades of combined experience from the pharmaceutical, biotechnology, and medical device industries.

CardiovascularMetabolic

Technology Platform

PDS-2™ System designed to harness HDL ('good cholesterol') to regress atherosclerotic plaques in arteries.

Opportunities

The primary opportunity is expanding the approved PDS-2™ System from the rare HoFH population into the vast market of patients with established atherosclerotic cardiovascular disease (ASCVD), where plaque regression is a major unmet need.
Success in this broader indication could position the company as a leader in a new treatment paradigm for heart disease.

Risk Factors

Key risks include the scientific and clinical challenge of translating plaque regression efficacy from severe HoFH to the general ASCVD population, the high cost and complexity of running large cardiovascular outcomes trials, and intense competition from large pharmaceutical companies pursuing next-generation cardiometabolic therapies.

Competitive Landscape

The competitive landscape includes large-cap pharma companies with dominant lipid-lowering drugs (e.g., statins, PCSK9 inhibitors) that manage risk but do not regress plaque, as well as other biotechs investigating novel anti-inflammatory and plaque-stabilizing pathways. HDL Therapeutics currently holds a unique position with an FDA-approved plaque-regressing therapy for HoFH.

More companies in Small Molecule Drugs →More companies in United States →